Latest From Exelixis Inc.
Two successful Phase III studies of Inlyta in combination with two distinct immunotherapies, including its own, Merck KGaA-partnered Bavencio, puts Pfizer in a very strong position in the advanced kidney cancer market.
2019 looks set to be a transformative year for Ipsen, with a pivotal clinical trial readout expected for combination Cabometyx in frontline kidney and liver cancer, and a series of deals promised by the company to investors looking for reassurance over long-term growth. CEO David Meek spoke to Scrip.
Merck & Co.’s IO powerhouse Keytruda has trumped Bavencio’s recent Inlyta combo PFS win in kidney cancer, with a OS and PFS combo hit of its own. But the field is getting increasingly crowded.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Exelixis Inc.
- Senior Management
Michael M Morrissey, PhD, Pres. & CEO
Christopher J Senner, EVP, CFO
Peter Lamb, PhD, EVP, Scientific Strategy & CSO
Gisela M Schwab, MD, Pres., Prod. Dev. & CMO
- Contact Info
Phone: (650) 837-7000
210 East Grand Ave.
P.O. Box 511 S. San Francisco, CA 94083-0511
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.